Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma
Reid W. Merryman(Harvard University), Philippe Armand(Harvard University), Robert Redd(Harvard University), Jennifer R. Brown(Dana-Farber Cancer Institute), Benjamin L. Lampson(Harvard University), Oreofe O. Odejide(Dana-Farber Cancer Institute), Robin Joyce(Beth Israel Deaconess Medical Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Gulrayz Ahmed(Medical College of Wisconsin), Kristin M McHugh(Dana-Farber Cancer Institute), Alex F. Herrera(City of Hope), Yi‐Bin Chen(Massachusetts General Hospital), Caron A. Jacobson(Dana-Farber Cancer Institute), Arnold S. Freedman(Otsuka (Japan)), Parastoo B. Dahi(Memorial Sloan Kettering Cancer Center), Erin Jeter(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Eric D. Jacobsen(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), Samuel Y. Ng(National Cancer Institute), Eleanor Taranto(Unknown)
Cited by 9
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k